Teva's business is encountering headwinds, including declining U.S. generics revenue. Read what this biotech plans to do in ...
Cite this: What's Next? Clinical Trials in Myelofibrosis - Medscape - Mar 06, 2025.
Alfred L. Garfall, MD, discusses the phase 2 BMT CTN 1902 trial of idecabtagene vicleucel in patients with multiple myeloma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback